Compare ACCL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | VTGN |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | Hong Kong | United States |
| Employees | 22 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 25.3M |
| IPO Year | N/A | 2014 |
| Metric | ACCL | VTGN |
|---|---|---|
| Price | $2.29 | $0.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 24.6K | ★ 1.2M |
| Earning Date | 05-20-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.23 | $0.20 |
| 52 Week High | $5.00 | $5.14 |
| Indicator | ACCL | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 79.16 | 38.66 |
| Support Level | $1.31 | $0.22 |
| Resistance Level | $2.34 | $0.65 |
| Average True Range (ATR) | 0.11 | 0.01 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 88.04 | 94.74 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.